Replimune

Image of a neon sign with the word no lit up next to an unlit yes
Biotech

Replimune's request for melanoma approval rejected by FDA

Investors sent the biotech’s share price down 76% to below $3 in premarket trading.
Nick Paul Taylor Jul 22, 2025 8:45am
Photo of a parachutes opened with a dark blue sky in the background

John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders

Mar 29, 2024 9:30am
end of the road road block shut down closed blocked

Replimune shares halve as skin cancer drug fails phase 2

Dec 5, 2023 10:35am
Parachute

New year, new C-suite execs—Chutes & Ladders

Jan 6, 2023 9:30am
exit

Replimune axes CMO role and CMO Pirzkall along with it

Aug 26, 2021 7:20am
Parachute

Genentech cancer exec lands at Replimune as CCO—Chutes & Ladders

Apr 23, 2021 9:30am